UCB SA (OTCMKTS:UCBJY) Short Interest Down 80.0% in December

UCB SA (OTCMKTS:UCBJY) saw a significant decline in short interest during the month of December. As of December 15th, there was short interest totalling 200 shares, a decline of 80.0% from the November 30th total of 1,000 shares. Based on an average daily trading volume, of 11,900 shares, the short-interest ratio is presently 0.0 days.

UCB Trading Up 0.2 %

UCBJY stock traded up $0.22 during trading on Friday, hitting $99.24. The company had a trading volume of 5,171 shares, compared to its average volume of 17,404. UCB has a fifty-two week low of $43.17 and a fifty-two week high of $100.01. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19. The business has a 50 day moving average of $95.93 and a 200 day moving average of $88.20.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.